The Hong Kong government is reportedly considering relaxing the registration system for new drugs, which would help expedite the introduction of new drugs into Hong Kong, including those approved by the National Medical Products Administration (NMPA). This move is expected to facilitate the use of Chinese-made medicines in Hong Kong and benefit patients in urgent need of medicines.
China Medical System Holdings Ltd., a healthcare company based in Shenzhen, China, has obtained an exclusive license for the first-line phosphate-lowering drug Velphoro(R) through its subsidiary. The license allows China Medical System to register, import, promote, distribute, use, and sell the drug in Mainland China, Hong Kong, Macao, and Taiwan. Velphoro(R) is the first iron-based, non-calcium phosphate binder approved by the National Medical Products Administration in China. It is used to control serum phosphorus levels in adults and pediatric patients with chronic kidney disease. The drug has been included in China's National Reimbursement Drug List and is expected to improve the quality of life for dialysis patients. China Medical System aims to expand its innovative product portfolio and kidney disease product portfolio with the addition of Velphoro(R) [c165e674] [29ef5fd9].